Lily Zou, Degron Therapeutics CEO
June 9, 2022 06:08 AM EDTUpdated 10:35 AM
Financing
Startups

Armed with li­brary of mol­e­c­u­lar glues, De­gron launch­es out of a Shang­hai lab

Paul Schloesser

Associate Editor

A transpa­cif­ic biotech fo­cused on mol­e­c­u­lar glues now has more funds to play with as it works to vie for Big Phar­ma’s at­ten­tion.

De­gron Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times